DATASET RE-READ 2026-11-2042 PROGRAMSNEXLIFE PRICES READ 2026-11-20EVERY FIGURE CARRIES ITS READ DATE
TopGLP1Providers.comverified price index
DATED PRICES

Fifty 410 review: November 2026 prices, terms and what to verify

As of November 20, 2026, Fifty 410’s own page lists tirzepatide $199 per 4-week program or $299 per 8-week program (not in all states); semaglutide $199 per 4-week program. On this site’s computed price-and-transparency score it has 23.5 of 40 points, position 8 of 27 compounded programs.

Released · Last reviewed · how we verify

Check Fifty 410’s current prices ↗

What Fifty 410 charges now

Fifty 410’s prices were read on its own page on November 20, 2026 (changed since the last read). This site compares programs on the all-in month-to-month price at the maintenance dose, which counts any required membership or program fee and leaves out first-month offers. A 28-day billing cycle means 13 charges a year, not 12.

Fifty 410, compounded GLP-1 prices read on its own page on November 20, 2026 (all-in: medication plus any required recurring fee; before tax)
MedicationMonth to month, all-inBilling basisLowest printed rateYear at month-to-month priceRead
Compounded tirzepatide$199per 28-day cycle$149.50 (8-week program at $299, not in all states)$2,587 (13 four-week cycles)2026-11-20
Compounded semaglutide$199per 28-day cycle$199 (4-week program)$2,587 (13 four-week cycles)2026-11-20

Fifty 410 on the computed score

On this site’s computed price-and-transparency score it has 23.5 of 40 points, position 8 of 27 compounded programs. The score covers the two parts of our seven-category methodology that can be checked for every program on the same day: pricing transparency (20 points) and total annual cost (20 points). The full ranking is on the rankings page.

How the computed score is built for Fifty 410 (prices read November 20, 2026; five checks at 4 points each, plus total annual cost scaled to the lowest year in the dataset)
CheckTirzepatideSemaglutide
prints a month-to-month priceyes (+4)yes (+4)
medication and care in one priceyes (+4)yes (+4)
same price at every doseno (0)no (0)
no membership feeyes (+4)yes (+4)
price read on its own page on November 20, 2026yes (+4)yes (+4)
Year at the month-to-month price$2,587$2,587
Total annual cost points7.9 of 207 of 20
Score for this drug23.9 of 4023 of 40

FDA warning letters

FDA’s warning-letter index lists warning letter 721481 (dated February 20, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to Fifty 410; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.

Limitations: five things to get in writing before you pay

Ask for the all-in price at your current dose and at the maintenance dose; the amount charged today and whether it recurs monthly or is prepaid; the licensed pharmacy that fills the prescription; the cancellation and refund terms, word for word; and what happens to your price when the dose goes up. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy.

Frequently asked

Does Fifty 410 charge a membership fee?

No required membership fee appeared on Fifty 410’s page when it was read on November 20, 2026; the figures above are the full recurring charge before tax.

Does Fifty 410 take insurance?

Not for compounded medication. Fifty 410 is a cash-pay program in this dataset (August 2026 capture), and insurers do not cover compounded GLP-1s. If your plan covers Zepbound or Wegovy, check that first, because a covered brand prescription usually costs less than any cash price.

Which states does Fifty 410 serve?

Fifty 410’s published coverage in the August 2026 capture was: not published. Telehealth prescribing depends on state licensing and changes often, so confirm your state at the start of the intake. The state pages list what each program publishes.

Fifty 410 tirzepatideFifty 410 vs EdenFifty 410 vs FoundFifty 410 vs Henry MedsFifty 410 vs Hims & HersRankingsPrice databaseAll providers

Sources

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.